Mark "Marty" Pagel, Ph.D.

Associate Professor
Biomedical Engineering and Chemistry
Office: Room 4949B, Arizona Cancer Center
Phone: (520)-404-7049
Fax: (520)-626-0395
Email: mpagel@u.arizona.edu
Mail Address: Room 4949B
Arizona Cancer Center
1515 North Campbell Ave.
Tucson, AZ 85724
Selected links:
• Contrast Agent Molecular Engineering Lab
• My Calendar
  Send Email to Request an Appointment

• Biomedical Engineering Program
• Department of Chemistry
• Arizona Cancer Center
• Arizona Research Labs
• Institute for Collaborative BioResearch (BIO5)
• Advanced Research Institute for Biomedical Imaging (ARIBI)
• Biomedical Magnetic Resonance Facility
• The University of Arizona

• Green Bay Packers
• Marty's Adventure Map

Research Summary

Our research focuses on the development of new responsive MRI contrast agents that detect the presence of functional or molecular markers of disease. We develop and apply these new MRI agents to non-invasively assess disease states in pre-clinical models of disease. Our research also focuses on the development of new contrast agents for Dynamic Contrast Enhancement MRI to assess tumor angiogenesis and anti-angiogenic therapies.

Recent Publications
•  Sheth VR, van Heeckeren RC, Wilson AG, van Heeckeren AM, Pagel MD. Monitoring Infection and Inflammation in Murine Models of Cystic Fibrosis with Magnetic Resonance Imaging, J Magn Reson Imaging, in press.
 
•  Yoo B, Raam MS, Rosenblum RM, Pagel MD. Enzyme-responsive PARACEST MRI contrast agents: A new biomedical imaging approach for studies of the proteasome. Contrast Media and Molecular Imaging, 2007, 2:189-198.
 
•  Liu G, Li Y, Pagel MD. Design and characterization of new irreversible responsive PARACEST MRI contrast agent that detects nitric oxide. Magn. Reson. Med., 2007, 58:1249-1256.
 
•  Yoo B, Pagel MD. An Overview of Responsive MRI Contrast Agents for Molecular Imaging. Frontiers in Bioscience, 2008, 13:1733-1752.
 
•  Yoo B, Pagel MD. Peptidyl Molecular Imaging Contrast Agents Using a New Solid Phase Peptide Synthesis Approach. Bioconj. Chem., 2007, 18:903-911.
 
•  Yoo B, Pagel MD. A PARACEST MRI contrast agent to detect enzyme activity. J. Am. Chem. Soc., 2006, 128(43):14032-14033.
 
•  Yoo B, Pagel MD. A facile synthesis of α-amino-DOTA as a versatile molecular imaging probe. Tetrahedron Lett,2006, 47:7327-7330.
 
•  Pagel MD, Baldwin SJ, O’Neal JM, Ornberg RL, Davis TW, Kotyk JK, Merits of Multiple Contrast Agents and Pixel-by-Pixel Analyses for Detection of Early Changes in Vascular Permabilities in Murine Tumor Models Following Drug Therapy and/or Radiation Therapy. Proc ISMRM 11:1250, 2003.
 
•  Pagel MD, Baldwin SJ, Rader RK, Kotyk JJ, Assessment of Anti-metastatic Drug Efficacy via Localization and Quantification of ex vivo Murine Bone Tumor Load Using High-Throughput MRI T1 Parametric Analysis, NMR in Biomed., 2006, 19:1-9.
 
•  Kotyk JJ, Pagel MD, Deppermann KL, Colletti RF, Hoffman NG, Yannakakis EJ, Das PK, Ackerman JJH, High-Throughput Determination of Oil Content in Corn Kernels Using Nuclear Magnetic Resonance Imaging. J Am. Oil Chem. Soc., 2005, 82:855-862.
 
•  Davis TW, O'Neal JM, Pagel MD, Zweifel, BS, Mehta PP, Heuvelman DM, Masferrer JL. Synergy between celecoxib and radiotherapy results from inhibition of COX-2 derived PGE2, a survival factor for tumor and associated vasculature. Cancer Res., 2004, 64:279-285.